Friday, 20 September 2019

Samsung to construct a new drug manufacturing plant

01 December 2015 | News | By BioSpectrum Bureau

Samsung to construct a new drug manufacturing plant

The new facility will be completed by 2018

The new facility will be completed by 2018

Singapore: Samsung BioLogics, biologic drug-manufacturing arm of Samsung Group said that it would invest 850 billion Korean won ($740 million) to construct a new biologic drug manufacturing facility in Songdo, South Korea, next to its two existing plants.

The company further mentioned that the new facility will double its production capacity and make it the world's largest contract drug maker.

The new facility, which Samsung said would be completed by September 2018, will have 180,000 liters of capacity.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls